Allogeneic hematopoietic stem cell transplantation for primary and secondary myelofibrosis
-
- Takeuchi Masahiro
- Department of Hematology, Chiba University Hospital
-
- Nakaseko Chiaki
- Department of Hematology, Chiba University Hospital
-
- Ohwada Chikako
- Department of Hematology, Chiba University Hospital
-
- Sato Yasunori
- Clinical Research Center, Chiba University Hospital
-
- Ohashi Kazuteru
- Division of Hematology, Tokyo Metropolitan Komagome Hospital
-
- Kakihana Kazuhiko
- Division of Hematology, Tokyo Metropolitan Komagome Hospital
-
- Mori Takehiko
- Department of Hematology, Keio University School of Medicine
-
- Aisa Yoshinobu
- Division of Hematology, Yokohama Municipal Citizenʼs Hospital
-
- Kanda Yoshinobu
- Department of Hematology, Saitama Medical Center, Jichi Medical University
-
- Takahashi Satoshi
- Division of Molecular Therapy, The Advanced Clinical Research Center, The Institute of Medical Science, The University of Tokyo
-
- Yokota Akira
- Department of Internal Medicine, Chiba Aoba Municipal Hospital
-
- Kawaguchi Takeharu
- Department of Hematology, Chiba University Hospital
-
- Saitoh Takayuki
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
-
- Hatsumi Nahoko
- Leukemia Research Center, Saiseikai Maebashi Hospital
-
- Taguchi Jun
- Department of Hematology, Shizuoka Red Cross Hospital
-
- Takasaki Hirotaka
- Department of Hematology, Kanagawa Cancer Center
-
- Kanamori Heiwa
- Department of Hematology, Kanagawa Cancer Center
-
- Maruta Atsuo
- Department of Hematology, Kanagawa Cancer Center
-
- Sakamaki Hisashi
- Division of Hematology, Tokyo Metropolitan Komagome Hospital
-
- Okamoto Shinichiro
- Department of Hematology, Keio University School of Medicine
書誌事項
- タイトル別名
-
- a retrospective, multicenter study of the Kanto Study Group for Cell Therapy (KSGCT)
この論文をさがす
説明
The optimal candidates and timing for allogeneic stem cell transplantation (allo-SCT) in patients with primary myelofibrosis (PMF) and secondary myelofibrosis (sMF) are unknown. We retrospectively examined the outcomes of PMF (n=13) and sMF (n=8)patients who underwent allo-SCT between 1997 and 2008. The median age at transplantation was 50 years (range, 21-60). Thirteen subjects (61.9%) received myeloablative conditioning. The source of hematopoietic cells was HLA-matched related (52.3%), -matched unrelated (33.3%), or -mismatched unrelated (9.5%) donors. All patients achieved engraftment, and the median time to neutrophil and platelet recovery was 19 (range, 13-36) and 75 (range, 15-411) days, respectively. With a median follow-up of 16.7(range, 1-134) months, overall survival (OS) at 60 months was 55.6% (95% CI, 34.0-77.0%). No significant differences in OS were observed between PMF and sMF patients and between myeloablative and reduced-intensity conditioning. HLA-mismatched donors, lower platelet count (<10×10 4 /μl), and previous blastic transformation were associated with a significantly worse prognosis. These data suggest that allo-SCT with myeloablative or reduced-intensity conditioning is potentially effective for PMF and sMF patients aged <60 years. However, a platelet count of <10×10 4 /μl is a strong adverse factor.
収録刊行物
-
- Journal of Hematopoietic Cell Transplantation
-
Journal of Hematopoietic Cell Transplantation 1 (1), 15-23, 2012
一般社団法人 日本造血・免疫細胞療法学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282680397356544
-
- NII論文ID
- 130001937524
-
- DOI
- 10.7889/hct.1.15
-
- ISSN
- 21865612
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- Crossref
- CiNii Articles
- OpenAIRE
-
- 抄録ライセンスフラグ
- 使用不可